NCT06524167 RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
| NCT ID | NCT06524167 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Thyroid Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-07-02 |
| Primary Completion | 2031-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2024-07-02 with a primary completion date of 2031-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a real-world study to observe the role of adjuvant radiotherapy in locally advanced recurrent high-risk thyroid cancer. The study included thyroid cancer that requires adjuvant radiotherapy to increase local control rate, excluding undifferentiated cancer. Local-regional recurrence free survival is the primary endpoint of the study.
Eligibility Criteria
Inclusion Criteria: * Patients voluntarily join this study and sign an informed consent form; * Age: ≥ 14 years old,\<80 years old, male or female not limited; * Thyroid cancer diagnosed by histopathology, including differentiated thyroid cancer, medullary carcinoma, poorly differentiated carcinoma, etc; * High risk of local late recurrence, meeting any of the following criteria: 1. The surgery did not achieve R0 resection; 2. After neoadjuvant therapy; 3. Pathological types with poor prognosis, such as poorly differentiated cancer, CASTLE, etc; 4. Thyroid cancer with obvious extracapsular invasion, invading important structures such as the esophagus, trachea, and recurrent laryngeal nerve, requiring adjuvant radiotherapy; 5. For patients with distant metastasis, researchers need to determine the value of local treatment; * The main organ functions are normal; * Good compliance and cooperation with follow-up. Exclusion Criteria: * Untreated thyroid cancer or thyroid cancer that has only undergone surgical biopsy; * Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group; * Previously received radiation therapy for the head and neck area; * Pregnant or lactating women; * There are other physical illnesses that affect patients' ability to receive standard treatment; * According to the researcher's judgment, there may be other factors that could force the subject to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data; * Individuals with claustrophobia who are unable to undergo radiation therapy; * Other patients deemed unsuitable for inclusion by the treating physician.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06524167 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 80 Years, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06524167 currently recruiting?
Yes, NCT06524167 is actively recruiting participants. Contact the research team at huangnsisi@fduan.edu.cn for enrollment information.
Where is the NCT06524167 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06524167 clinical trial?
NCT06524167 is sponsored by Fudan University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.